Analysis of risk factors for massive bone graft infection recurrence following bone sarcomas resections

Title

Code

GRAFTINF

Type

Osservazionale

Start Year

2025

Status

In Corso

Principal Investigator

051-6366511

luca.cevolani@ior.it

Cevolani Luca, MD

3rd Orthopaedic and Traumatologic Clinic prevalently Oncologic

Operational unit that carry out the study

complex unit

Clinica Ortopedica e Traumatologica III a prevalente indirizzo Oncologico

Director

Donati Davide Maria, MD

Go to the details >>

Description

Studio promosso da IRCCS Azienda Ospedaliero-universitaria Policlinico di Sant’Orsola, UOC Ortopedia e Traumatologia.

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio prot. GRAFTINF

Tuesday 8 April 2025, 11:30

PG0004637_2025_Stampa_unica.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

Sito Web Istituto Ortopedico Rizzoli

Analysis of risk factors for massive bone graft infection recurrence following bone sarcomas resections

Principal Investigator

Operational unit that carry out the study

Description

Documents and Videos attachament

You might also be interested in